Corcept Therapeutics Inc
CORTHealthcare|Biotechnology|USA
$91.88
-1.37 (-1.47%)
DCF (FCF)
$25.10
Tangible Book
$5.94
Graham Number
$6.84
Earnings Power
$19.15
Upcoming Data Readouts (9)
Aug 2026
Est. completion
P2Ovarian Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341n=270
Sep 2026
Est. completion
P1P2Neoplasms
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373n=50
Sep 2026
Est. completion
P2Nonalcoholic Steatohepatitis (NASH)
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219n=175
Sep 2026
Est. completion
P2Treatment-resistant PTSD
REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
NCT06689254n=60
Oct 2026
Est. completion
P2Amyotrophic Lateral Sclerosis
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324n=279
Oct 2026
Est. completion
P1Nonalcoholic Steatohepatitis (NASH)
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663n=15
Dec 2026
Est. completion
P2Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198n=125
Sep 2027
Est. completion
P2Adenocarcinoma
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317n=80
Oct 2027
Est. completion
P2Metastatic Breast Cancer
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769n=201
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2025
P3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408